Send to:

Choose Destination
See comment in PubMed Commons below
J Chemother. 1999 Oct;11(5):331-7.

Emergence of resistance during mupirocin treatment: is it a problem in clinical practice?

Author information

  • 1SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, U.K.


Mupirocin (pseudomonic acid A) is indicated for primary and secondary skin infections, and for the eradication of nasal colonization of Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This paper reviews the mechanisms by which resistance to mupirocin can develop, discusses clinically relevant breakpoints, and the clinical significance of reports of resistance. Following more than 10 years' use, short courses of treatment, even when repeated, are associated with remarkably little resistance and this resistance is unlikely to be clinically significant.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk